Development
Cullinan Therapeutics, Inc.
CGEM
$8.08
$0.141.76%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.64M | 10.98M | 10.21M | 10.66M | 13.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.49M | 44.80M | 37.61M | 62.76M | 34.61M |
| Operating Income | -45.49M | -44.80M | -37.61M | -62.76M | -34.61M |
| Income Before Tax | -39.69M | -39.18M | -32.21M | -58.14M | -28.95M |
| Income Tax Expenses | -14.12M | -- | -- | -- | -1.86M |
| Earnings from Continuing Operations | -25.56M | -39.18M | -32.21M | -58.14M | -27.09M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 1.76M | -- | -- | 179.00K | 306.00K |
| Net Income | -23.80M | -39.18M | -32.21M | -57.96M | -26.78M |
| EBIT | -45.49M | -44.80M | -37.61M | -62.76M | -34.61M |
| EBITDA | -45.41M | -44.72M | -37.52M | -62.68M | -34.55M |
| EPS Basic | -0.56 | -0.92 | -0.81 | -1.42 | -0.59 |
| Normalized Basic EPS | -0.54 | -0.57 | -0.50 | -0.89 | -0.42 |
| EPS Diluted | -0.56 | -0.92 | -0.82 | -1.42 | -0.59 |
| Normalized Diluted EPS | -0.54 | -0.57 | -0.50 | -0.89 | -0.42 |
| Average Basic Shares Outstanding | 42.79M | 42.73M | 39.95M | 40.68M | 45.75M |
| Average Diluted Shares Outstanding | 42.79M | 42.73M | 39.95M | 40.68M | 45.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |